- Neos is buffeted by the pandemic and wholesaler inventory levels which have produced declines in subscriptions and revenues.
- The full impact of the pandemic has yet to be felt as Q2 will be considerably worse.
- The company embarked on cost cutting, but for the shares to recover, sales need to grow well above their pre-pandemic levels, which is far from a given.
Neos Therapeutics Is Hitting A Considerable Air Pocket
September 9th, 2020 · No Comments